Clinical Trials
42 trialsNCT01479842 2026-03-23
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06483048 2026-03-16
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Mayo Clinic
Phase 1 Recruiting
NCT06191887 2026-02-13
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
Phase 1 Recruiting
NCT04223765 2026-01-20
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT03602157 2026-01-06
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06043713 2025-12-19
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations
Fred Hutchinson Cancer Center
Phase 1 Recruiting
NCT03696784 2025-12-08
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03352765 2025-12-04
A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT02996773 2025-11-10
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
Phase 1 Completed
NCT02315157 2025-10-15
Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma
Thomas Jefferson University
Phase 1 Withdrawn
NCT02153580 2025-10-06
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
City of Hope Medical Center
Phase 1 Active not recruiting
NCT07169565 2025-09-11
Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Not yet recruiting
NCT04892277 2025-07-01
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Mayo Clinic
Phase 1 Recruiting
NCT01352312 2025-04-29
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Thomas Jefferson University
Phase 1 Terminated
NCT04809766 2025-04-20
Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Fred Hutchinson Cancer Center
Phase 1 Terminated
NCT06094842 2025-04-01
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
Fred Hutchinson Cancer Center
Phase 1 Withdrawn
NCT03524235 2024-11-12
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Cedars-Sinai Medical Center
Phase 1 Completed
NCT02148913 2024-07-26
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
Corewell Health West
Phase 1 Completed
NCT04083898 2024-03-19
Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma
Washington University School of Medicine
Phase 1 Terminated
NCT02168140 2024-02-13
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Wake Forest University Health Sciences
Phase 1 Completed
NCT02728531 2023-11-01
Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
Washington University School of Medicine
Phase 1 Completed
NCT02257242 2023-02-09
BRiM
Brown University
Phase 1 Completed
NCT02187133 2021-04-23
Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
University of California, San Francisco
Phase 1 Completed
NCT02095834 2021-01-11
Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01491841 2020-03-04
BRP
Duke University
Phase 1 Completed
NCT01429025 2019-10-08
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT00880815 2019-06-03
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02240719 2019-01-04
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
University of California, Davis
Phase 1 Completed
NCT02168907 2018-07-02
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Wake Forest University Health Sciences
Phase 1 Terminated
NCT00837928 2018-05-17
Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01832922 2018-03-30
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT01400685 2018-01-25
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL
Massachusetts General Hospital
Phase 1 Completed
NCT02130869 2017-12-22
A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01042704 2017-07-31
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
University of Pittsburgh
Phase 1 Completed
NCT02194374 2017-06-12
Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT01900509 2017-03-22
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01871675 2016-07-11
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
SCRI Development Innovations, LLC
Phase 1 Completed
NCT01152203 2015-11-18
Bendamustine and Bevacizumab for Advanced Cancers
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00864942 2015-03-13
Phase I BLR
Georgetown University
Phase 1 Completed
NCT00947388 2013-08-22
Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT00879073 2012-12-18
Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT00661739 2011-09-02
RiTa
GBG Forschungs GmbH
Phase 1 Completed